258 related articles for article (PubMed ID: 34889159)
1. Concatenation of molecular docking and molecular simulation of BACE-1, γ-secretase targeted ligands: in pursuit of Alzheimer's treatment.
Jabir NR; Rehman MT; Alsolami K; Shakil S; Zughaibi TA; Alserihi RF; Khan MS; AlAjmi MF; Tabrez S
Ann Med; 2021 Dec; 53(1):2332-2344. PubMed ID: 34889159
[TBL] [Abstract][Full Text] [Related]
2. Identification of Butyrylcholinesterase and Monoamine Oxidase B Targeted Ligands and their Putative Application in Alzheimer's Treatment: A Computational Strategy.
Jabir NR; Rehman MT; Tabrez S; Alserihi RF; AlAjmi MF; Khan MS; Husain FM; Ahmed BA
Curr Pharm Des; 2021; 27(20):2425-2434. PubMed ID: 33634754
[TBL] [Abstract][Full Text] [Related]
3. In silico screening of glycogen synthase kinase-3β targeted ligands against acetylcholinesterase and its probable relevance to Alzheimer's disease.
Jabir NR; Shakil S; Tabrez S; Khan MS; Rehman MT; Ahmed BA
J Biomol Struct Dyn; 2021 Sep; 39(14):5083-5092. PubMed ID: 32588759
[TBL] [Abstract][Full Text] [Related]
4. Dynamic Simulation, Docking and DFT Studies Applied to a Set of Anti-Acetylcholinesterase Inhibitors in the enzyme β-Secretase (BACE-1): An Important Therapeutic Target in Alzheimer`s disease.
Silva-Junior EF; Barcellos Franca PH; Quintans-Junior LJ; Mendonca-Junior FJB; Scotti L; Scotti MT; de Aquino TM; de Araujo-Junior JX
Curr Comput Aided Drug Des; 2017 Nov; 13(4):266-274. PubMed ID: 28382866
[TBL] [Abstract][Full Text] [Related]
5. Repurposing of phyto-ligand molecules from the honey bee products for Alzheimer's disease as novel inhibitors of BACE-1: small molecule bioinformatics strategies as amyloid-based therapy.
Nisa N; Rasmita B; Arati C; Uditraj C; Siddhartha R; Dinata R; Bhanushree B; Bidanchi RM; Manikandan B; Laskar SA; Abinash G; Pori B; Roy VK; Gurusubramanian G
Environ Sci Pollut Res Int; 2023 Apr; 30(17):51143-51169. PubMed ID: 36808033
[TBL] [Abstract][Full Text] [Related]
6. Exploring the Molecular Structural Requirements of Flavonoids as Beta- Secretase-1 Inhibitors Using Molecular Modeling Studies.
More UA; Noolvi MN; Kumar D; Tripathi A
Curr Drug Discov Technol; 2023; 20(3):e290323215095. PubMed ID: 36999415
[TBL] [Abstract][Full Text] [Related]
7. Inkjet printing-based β-secretase fluorescence resonance energy transfer (FRET) assay for screening of potential β-secretase inhibitors of Alzheimer's disease.
Lee J; Samson AAS; Song JM
Anal Chim Acta; 2018 Aug; 1022():89-95. PubMed ID: 29729742
[TBL] [Abstract][Full Text] [Related]
8. Scaffold Morphing and In Silico Design of Potential BACE-1 (β-Secretase) Inhibitors: A Hope for a Newer Dawn in Anti-Alzheimer Therapeutics.
Bhatia S; Singh M; Sharma P; Mujwar S; Singh V; Mishra KK; Singh TG; Singh T; Ahmad SF
Molecules; 2023 Aug; 28(16):. PubMed ID: 37630283
[TBL] [Abstract][Full Text] [Related]
9. Molecular docking and molecular dynamics approach to identify potential compounds in
Tung BT; Hang TTT; Kim NB; Nhung NH; Linh VK; Thu DK
J Complement Integr Med; 2022 Dec; 19(4):955-965. PubMed ID: 35621378
[TBL] [Abstract][Full Text] [Related]
10. Computer-Aided Drug Design of β-Secretase, γ-Secretase and Anti-Tau Inhibitors for the Discovery of Novel Alzheimer's Therapeutics.
Mouchlis VD; Melagraki G; Zacharia LC; Afantitis A
Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 31973122
[TBL] [Abstract][Full Text] [Related]
11. Identification of High-affinity Small Molecules Targeting Gamma Secretase for the Treatment of Alzheimer's Disease.
Ali MA; Vuree S; Goud H; Hussain T; Nayarisseri A; Singh SK
Curr Top Med Chem; 2019; 19(13):1173-1187. PubMed ID: 31244427
[TBL] [Abstract][Full Text] [Related]
12. Design, Synthesis and Evaluation of 2,4,6-substituted Pyrimidine Derivatives as BACE-1 Inhibitor: Plausible Lead for Alzheimer's Disease.
Jain P; Wadhwa PK; Jadhav HR
Med Chem; 2021; 17(10):1194-1206. PubMed ID: 33349218
[TBL] [Abstract][Full Text] [Related]
13. Aptiom (eslicarbazepine acetate) as a dual inhibitor of β-secretase and voltage-gated sodium channel: advancement in Alzheimer's disease-epilepsy linkage via an enzoinformatics study.
Shaikh S; Rizvi SM; Hameed N; Biswas D; Khan M; Shakil S; Kamal MA
CNS Neurol Disord Drug Targets; 2014; 13(7):1258-62. PubMed ID: 25230222
[TBL] [Abstract][Full Text] [Related]
14.
Galeana-Ascencio RA; Mendieta L; Limon DI; Gnecco D; Terán JL; Orea ML; Carrasco-Carballo A
Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37175873
[TBL] [Abstract][Full Text] [Related]
15. Study on the active mechanism of β-secretase inhibitors by molecular simulations.
Tian YL; Lv M; Li JJ; Xu T; Zhai HL; Zhang XY
Eur J Pharm Sci; 2015 Aug; 76():138-48. PubMed ID: 25965961
[TBL] [Abstract][Full Text] [Related]
16. In Silico Inhibition of BACE-1 by Selective Phytochemicals as Novel Potential Inhibitors: Molecular Docking and DFT Studies.
Arif N; Subhani A; Hussain W; Rasool N
Curr Drug Discov Technol; 2020; 17(3):397-411. PubMed ID: 30767744
[TBL] [Abstract][Full Text] [Related]
17. Docking, molecular dynamics, binding energy-MM-PBSA studies of naphthofuran derivatives to identify potential dual inhibitors against BACE-1 and GSK-3β.
Kumar A; Srivastava G; Negi AS; Sharma A
J Biomol Struct Dyn; 2019 Feb; 37(2):275-290. PubMed ID: 29310523
[TBL] [Abstract][Full Text] [Related]
18. Disease-modifying approach to the treatment of Alzheimer's disease: from alpha-secretase activators to gamma-secretase inhibitors and modulators.
Panza F; Solfrizzi V; Frisardi V; Capurso C; D'Introno A; Colacicco AM; Vendemiale G; Capurso A; Imbimbo BP
Drugs Aging; 2009; 26(7):537-55. PubMed ID: 19655822
[TBL] [Abstract][Full Text] [Related]
19. In silico repurposing of antipsychotic drugs for Alzheimer's disease.
Kumar S; Chowdhury S; Kumar S
BMC Neurosci; 2017 Oct; 18(1):76. PubMed ID: 29078760
[TBL] [Abstract][Full Text] [Related]
20. Guanidine-based β amyloid precursor protein cleavage enzyme 1 (BACE-1) inhibitors for the Alzheimer's disease (AD): A review.
Gehlot P; Kumar S; Kumar Vyas V; Singh Choudhary B; Sharma M; Malik R
Bioorg Med Chem; 2022 Nov; 74():117047. PubMed ID: 36265268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
